Literature DB >> 27995906

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.

Paul Y Kwo1, Stanley M Cohen2, Joseph K Lim3.   

Abstract

Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cholestasis. Multiple studies have demonstrated that the presence of an elevated ALT has been associated with increased liver-related mortality. A true healthy normal ALT level ranges from 29 to 33 IU/l for males, 19 to 25 IU/l for females and levels above this should be assessed. The degree of elevation of ALT and or AST in the clinical setting helps guide the evaluation. The evaluation of hepatocellular injury includes testing for viral hepatitis A, B, and C, assessment for nonalcoholic fatty liver disease and alcoholic liver disease, screening for hereditary hemochromatosis, autoimmune hepatitis, Wilson's disease, and alpha-1 antitrypsin deficiency. In addition, a history of prescribed and over-the-counter medicines should be sought. For the evaluation of an alkaline phosphatase elevation determined to be of hepatic origin, testing for primary biliary cholangitis and primary sclerosing cholangitis should be undertaken. Total bilirubin elevation can occur in either cholestatic or hepatocellular diseases. Elevated total serum bilirubin levels should be fractionated to direct and indirect bilirubin fractions and an elevated serum conjugated bilirubin implies hepatocellular disease or biliary obstruction in most settings. A liver biopsy may be considered when serologic testing and imaging fails to elucidate a diagnosis, to stage a condition, or when multiple diagnoses are possible.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27995906     DOI: 10.1038/ajg.2016.517

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  94 in total

1.  Alanine aminotransferase levels: what's normal?

Authors:  Marshall M Kaplan
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

2.  UNCONJUGATED HYPERBILIRUBINEMIA IN THE ABSENCE OF OVERT HEMOLYSIS. IMPORTANCE OF ACQUIRED DISEASE AS AN ETIOLOGIC FACTOR IN 366 ADOLESCENT AND ADULT SUBJECTS.

Authors:  R A LEVINE; G KLATSKIN
Journal:  Am J Med       Date:  1964-04       Impact factor: 4.965

3.  Primary biliary cirrhosis.

Authors:  Keith D Lindor; M Eric Gershwin; Raoul Poupon; Marshall Kaplan; Nora V Bergasa; E Jenny Heathcote
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

4.  Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels.

Authors:  Brent A Neuschwander-Tetri; Aynur Unalp; Michael H Creer
Journal:  Arch Intern Med       Date:  2008-03-24

5.  Upper limits of normal for alanine aminotransferase activity in the United States population.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

6.  Persistent alanine aminotransferase elevation in healthy Swedish blood donors--mainly caused by obesity.

Authors:  R Wejstål; G Hansson; A Lindholm; G Norkrans
Journal:  Vox Sang       Date:  1988       Impact factor: 2.144

7.  The rational clinical examination. Physical examination of the liver.

Authors:  C D Naylor
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

Review 8.  Gastrointestinal and hepatic manifestations of human ehrlichiosis: 8 cases and a review of the literature.

Authors:  A K Nutt; J Raufman
Journal:  Dig Dis       Date:  1999       Impact factor: 2.404

9.  Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.

Authors:  Stefan Zeuzem; Moisés Diago; Edward Gane; K Rajender Reddy; Paul Pockros; Daniele Prati; Mitchell Shiffman; Patrizia Farci; Norman Gitlin; Christopher B O'Brien; François Lamour; Pilar Lardelli
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

10.  High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking.

Authors:  H Nyblom; U Berggren; J Balldin; R Olsson
Journal:  Alcohol Alcohol       Date:  2004 Jul-Aug       Impact factor: 2.826

View more
  191 in total

1.  Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.

Authors:  Katie Witkiewitz; Henry R Kranzler; Kevin A Hallgren; Stephanie S O'Malley; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Karl F Mann; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2018-11-05       Impact factor: 3.455

2.  The Association of Abnormal Liver Tests with Hepatitis C Testing in Primary Care.

Authors:  Andrew D Schreiner; John Bian; Jingwen Zhang; Z Merle Haulsee; Justin Marsden; Valerie Durkalski-Mauldin; Patrick D Mauldin; William P Moran; Don C Rockey
Journal:  Am J Med       Date:  2019-07-29       Impact factor: 4.965

3.  Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit.

Authors:  Yaron Rotman; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2017-03-03       Impact factor: 17.425

4.  How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool.

Authors:  Varun Takyar; Anand Nath; Andrea Beri; Ahmed M Gharib; Yaron Rotman
Journal:  Hepatology       Date:  2017-07-27       Impact factor: 17.425

5.  Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study.

Authors:  Kali Zhou; Norah A Terrault
Journal:  Clin Gastroenterol Hepatol       Date:  2019-06-04       Impact factor: 11.382

Review 6.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

7.  Don't Miss the BoAAT: Correctly Diagnosing Acute-on-Chronic Liver Disease.

Authors:  Zain A Sobani; Graziella R Paniz; Morgan Wong; Denis M McCarthy
Journal:  Dig Dis Sci       Date:  2019-10       Impact factor: 3.199

8.  Abnormal Liver Enzymes.

Authors:  John Bian; Andrew D Schreiner; Don C Rockey
Journal:  J Gen Intern Med       Date:  2019-09       Impact factor: 5.128

9.  Abnormal Liver Enzymes.

Authors:  Shih-Wei Lai
Journal:  J Gen Intern Med       Date:  2019-09       Impact factor: 5.128

10.  Associations of Race with Follow-up Patterns After Initial Abnormal Liver Tests in Primary Care.

Authors:  John Bian; Andrew D Schreiner; Jingwen Zhang; Samuel O Schumann; Don C Rockey; Patrick D Mauldin; William P Moran
Journal:  J Gen Intern Med       Date:  2018-10       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.